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Summary Calcitriol (1 a ,25-dihydroxyvitamin Dj), applied topically in an ointment base, has been shown to be
effective in the treatment of chronic plaque psoriasis. This open study was designed to assess the 
safety and tolerability of 3 /./,g/g calcitriol ointment applied twice daily over treatment periods of up to 
78 weeks. In the 253 evaluable patients with chronic plaque psoriasis no clinically relevant changes 
were observed in the baseline/end-point analyses of mean serum levels of total calcium, albumin- 
adjusted total calcium, phosphorus and creatinine, and plasma calcitriol levels. Mean values of 24-h 
urinary calcium, phosphorus, creatinine and hydroxyproline excretions, creatinine clearance and 
mean urinary calcium/creatinine ratio also did not show clinically relevant changes in the baseline/ 
end-point analyses. The treatment was well tolerated, with no serious adverse events occurring 
during the course of the study. Eight patients withdrew from the study due to adverse events which, 
although not serious, were thought to be treatment-related: in seven patients skin irritation 
reactions and in one case a transient asymptomatic slight hypercalcaemia was observed. In 
addition, assessments of global severity, global improvement and Psoriasis Area and Severity 
Index scores confirmed the therapeutic efficacy of twice daily 3 //g/g calcitriol ointment demon­
strated in an earlier controlled study. In conclusion, this study demonstrated that twice daily 
application of 3 /¿g/g calcitriol ointment is safe and well-tolerated in the treatment of chronic plaque 
psoriasis.
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vitro 1 1 and a specific receptor for calcitriol has been
on human
dermal
kcratinocytes and 
Uso exerts effects on the
c /
immune system. These properties of calcitriol sug-
be useful for the clinical manage- 
ative skin 
ies have
tiS, t
gesled that it mi 
ment of hyperpr 
of recent clinical 
applied topically in an ointment base, is effective for the
I 1treatment of chronic plaque psoriasis/ These studies 
have been relatively short-term, however, with active 
treatment of a maximum of 6 weeks, and longer studies
are required to assess and tolerability of
calcitriol ointment as well as its efficacy in long-term 
treatment.
The aim of the study reported here was to assess the 
long-term safely, e
in pi
acy of 5/i.g/g 
ointment, applied twice daily to skin lesions 
s with chronic plaque psoriasis.
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Patients and methods
Two hundred and fifty-seven out-patients with chronic 
plaque psoriasis were enrolled in this open, long-term, 
multicentre study, designed to assess the safety, toler- 
ability and efficacy of twice daily application of 3 ¡.ig/g
calcitrici ointment. All gave wr
informed consent to participate in the study which 
was conducted according to the principles established
in Declaration of i. E
approval was obtained in the 20 participating centres.
Patients were selected at a screening visit and were 
excluded from the study if they were suffering lrom 
other types of psoriasis; had received any systemic or 
intralesional photo(chemo)therapy for psoriasis during 
the previous 2 months; had used topical 
therapy, with the exception of emulsifying ointment 
and/or tar shampoos during the week before the start of 
therapy; were receiving any concomitant medication or 
were suffering from any diseases (including skin infec­
tions) which might interfere with the assessment of the 
efficacy, safety or tolerability of the study drugs. 
Patients were also excluded if they had known hyper­
sensitivity to vitamin D or its analogues. Women of 
child-bearing potential had to have a pregnancy test to 
rule out pregnancy prior to enrolment in the study and 
every 3 months during treatment, and were required to 
be using an effective method of contraception for the 
duration of the study.
At a screening visit the general health of the patient 
was assessed and 1 week later at the baseline visit (day 
1) patients were provided with 3 f t g / g  calcitriol oint­
ment for twice daily application to all psoriatic lesions 
on the body, except those on the head. No occlusion was 
to be used, and the patients could wash off the ointment 
8-1.2 h after application. A cut-off date was defined 18
months after of the first I
meant that not all patients received tre 
full 18 months.
foi* ra
Laboratory assessments of parameters rellecting
calcium and phosphorus homeostasis were performed 
at each visit. Creatinine clearance and urinary calcium/ 
creatinine ratio were calculated. In addition, in one 
centre serum levels of parathyroid hormone (PTH) and 
2 5-hydroxyvitamin D and urinary hydroxyproline 
excretion were also measured at baseline and end­
point. A lull general health assessment, was carried 
out at the final visit.
The primary efficacy variable was the overall global 
improvement rating.12 Changes in
were scored on a six-point rating scale, at weeks 2, 4, 
8, 1 3 up to maximally week 78 of treatment, always in 
comparison with baseline. In addition, the Psoriasis 
Area and Severity Index /T' Am' 13 ns
isits. Pruri
it base­
an d
(head not included) and scores
and at each
overall global severity 14 of the treated lesions were 
also scored. At one centre skin biopsies were taken to 
investigate how and to what extent the inflammatory, 
proliferative and differentiative components of psoriasis 
were affected by calcitriol treatment. These have been
I c
reported elsewhere.
One of the objectives of this study was to assess the 
relapse rate in patients whose chronic plaque psoriasis 
had cleared or considerably improved with treatment.
vS re I a relapse were í to come to
clinic for assessment of the PAS1 score, pruritus and 
overall global severity. According to the protocol of
a relapse within 3trial, only patients s 
could re-enter
The non-parametrie, 
rank test was used to c
tory and vital signs) data
Wilcoxon signed- 
? baseline safety (labora­
dle end-point data.
Four of the 257 patients who entered the study had 
neither safety nor efficacy data after receiving study 
medication and were excluded from all analyses. Demo­
graphic data and disease details of the 25 5 evaluable
Characteristic
Males (a 15S) teníalos (a 9X1 Total (»
mean ± St) mean ± SI)
2S 5)
mean I SI)
Table I. Demographic dala anil disease 
characteristics of evaluable patients
.  »  r , * i  ~  .  i  i  • ,  ,  -  -
Age (years)
Weight (kg)
Height (cm)
History of psoriasis (months)
Total body surface area involved (%)
4 2 4  ±  12-4 
81-7-1-12-9 
1 76-4 ±  6-9 
197-8 ±  142-7 
14-8 ±  15*3
41-5 ± 1 i'7 
67-1 ± 14-4 
1.6 H  ± 7-5 
21 M I. 1 Î6*9
127 ± 12-4
42-1 1 12-9 
76-0 i ,  1 5-2 
1 71*3 i  9 • 6 
202-9 1 140-4 
14-0 .1 14-2
n, number of patients. 
SI), standard deviation.
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• are summarized in Table 1. A total of 219 
patients were treated continuously lor at least 3 
months, 149 for at least 6 months, 75 patients for at 
least 12 months and 16 patients for at least .18 months.
Forty-six patients (18%) withdrew from the study 
prematurely because their psoriasis improved or 
ared, seven (2-8%) withdrew due to local intoler­
ance and one (04% ) due to hypercalcaemia. 
hundred and eight patients (42*7%) were withdrawn
to lack of efficacy. However, included in
re were patients
weeks or of
treatment but then showed no further improvement 
or some deterioration upon continued treatment. (This 
is not uncommon in long-term studies of this type.)
changes were observed in baseline/end-point
analyses of any laboratory parameter. Blood bio­
baseline/end-point analyses for calcium, 
albumin-adjusted calcium, phosphorus, creatinine, cal- 
citriol, PTH and 2 5-hydroxyvitamin D are summarized 
in Table 2. The mean values of 24-h urinary calcium, 
phosphorus, creatinine and hydroxyproline excretion, 
urinary calcium/creatinine ratio and creatinine clear­
ance did not show clinically relevant changes in the 
baseline/end-point analyses. The mean 
diastolic blood pressure and mean 
remained well within the normal range throughout
and baseline/end-point analysis did not
reveal any clinically changes in
The actual amount of ointment was
dent on the size of the lesions and the thickness of the 
applied layer of ointment. Patients were asked to return 
all tubes at the end of the study. Of the 80 patients who 
returned all the mean quantity of 
ointment used was 6g/day (range l-2 4 g /d ay ) . 
Twenty-four patients (30% of those patients who 
returned all tubes) used more than 1000 g calcitriol 
ointment and eight (10%) more than 2000 g during 
their treatment period. Five patients (6%) used on 
average more than 15 g ointment daily, while 13 
patients (16%) used more than 10 g daily.
No serious adverse events or deaths occurred during 
the course of the study. Fifteen per cent of patients 
experienced a transient skin irritation reaction at some
were generally mild. Eight
due to adverse
T reac
patients withdrew from 
events which, though not serious, were thought to be 
related to the study medication. Seven of these were 
considered to be skin irritation reactions and one
six (40-1%) patie
improvement at
* or con-
compared with
and clearance of psoriasis was repot in
39 (16*3%) patients. Forty-six patients who showed 
clearing or considerable improvement of 
were withdrawn from the study due to this outcome. 
Eleven (23%) of these patients relapsed within 3 months 
and subsequently re-entered 
remaining group of 36
study. From the 
a relapse after 3 
months was reported in six patients, and they were 
subsequently also re-entered into the study (although 
this should be considered a protocol violation).
The number of pad severe or very severe 
psoriasis fell from 120 (47*4%) at baseline to 54
(2.1*4%) at end-point, while the number with none or 
slight psoriasis increased from 19 (7-5%) to 98 (38*8%).
uritus showed a significant improvement over 
course of the study. At baseline, 4-3% of the patients 
complained of severe, distressing pruritus, which had 
fallen to 1*2% at the 3- and 12-month assessments. At
patient 
hypercalcaemia.
a transient start of the study, 1 7% of patients had no
specific complaint of pruritus, but this had improved
No statistically significant and relevant to 48-4% at 3-month md î8*7% at
Table 2. Blood biochemistry: baseline/end-point analyses
Parameter //
Baseline 
mean 1 SI) a
Knd-poinl 
mean i  SI) P-value
». « y .-» --» » ..-" ''- - .  . t '»n*.«» .... ... >.> ----, . .M,vin>i< ••■i " • 'r  • w* • .niw* • •> «J ----- - ....... ..r> ...... . . . --—, ,, ^  .* I ...... .... . ,/ .
Calcium— total (mmol/I)
Calcium— total adjusted (mmol/I) 
Phosphorus (mmol/1)
Calcitriol (pg/ml)
2 5-hydroxy vitamin Dj //. g/1) 
Parathyroid horm one (nmol/1)
247
244
238
228
26
31
2 • Ì 5 5 :1: (>108 
2 -2 2 2  :i: 0-1 12 
1-137 ±  0-19 } 
40-29 ±  I 5-62 
1 34-69 ±  50-32 
0-3 32 ± 0 -1  15
224 
22 3 
222 
2 50
30
31
2- 34 3 ±  0-1 12 
2-216 ±  0-119 
1-1 14 ±  0-20 3 
42-12 ±  17-14 
122-97 ±  5 6 • 31 
0-325 1 0-120
0-5016 
()■ Ì795 
0-4( )64 
0 - 11)42 
0-1619 
0-5500
n, number of patients.
SI), standard deviation.
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Table 3. Psoriasis Area and Severity Index (PASl) score
Assessment Lime n Absolute score Percentage r
Baseline 
3 months 
12 months 
18 months 
Hnd-point
25 3
253
26 
2 5 3
9-71 
4-24 
4-23 
4-08 
4-32
53-24
54-28 
59-59 
51 *24
n, number of patients,
end-point. The PAS I score1 b showed a marked improve­
ment after 3 months treatment (53*2% reduction in 
score), which was maintained over the whole course of 
the study (see Table 3).
From 47 patients who to enter
relapse phase of the study, 11 (23%) relapsed within 3 
months, and a relapse was reported in a further six 
patients after 3 months. This relapse rate is considerably 
lower than that observed after topical corticosteroid
srapy t 19 and the possible mechanisms involved war­
rant further investigation. 
In conclusion,
twice daily application of 3 ftg/g calcitriol ointment is 
safe and well tolerated in the long-term treatment
ic plaque psoriasis.
Acknowledgment
This study was fully sponsored by Solvay-Duphar B.V., 
Weesp, The Netherlands.
Discussion
Twice daily application of 3 /;,g/g calcitriol ointment for 
up to 78 weeks had no clinically relevant effects on 
calcium and phosphorus homeostasis and renal func­
tion in this large group of patients with chronic plaque 
psoriasis. These results confirm and extend the findings
n i f f
of previously reported short-term studies and they 
appear to refute suggestions that calcitriol
treatment may be unsafe due to unwanted effects on 
systemic calcium homeostasis. For, even in patients 
who used large quantities of the ointment for many 
months, no noteworthy changes were seen in serum 
total calcium levels or urinary calcium excretion.
The treatment was generally very well tolerated and 
there were no reports of serious adverse events, it is an 
important advance of antipsoriatic therapy that vitamin 
Dj analogues permit; safe long-term management of
psoriasis over many In a
161 patients treated for up to 1 an
ointment containing vitamin l)¡ ana-
(50//,
and well tolerated.18 In 
withdrawal due to tret
, also to
present study the rate of 
-associated local intoler-
ance was 2-8% (seven of 25 3 patients), while in the 
long-term study with ealeipotriolls 5-6% (nine of 161) 
of patients had to discontinue treatment due to irrit ation.
The open design of this study means that no firm 
conclusions can be drawn as to the long-term efficacy of 
twice daily 3 //,g/g calcitriol ointment in chronic plaque 
psoriasis. The results obtained for the assessments of the 
global improvement scale, the PAS1 score and the global 
severity scale appear, however, to confirm the thera-
'acy in an earlier contr
study, which used this regimen for up to 6 weeks. 8
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